retatrutide ly3437943 phase 2 trial obesity nejm 2023 Research Guide: What the Data Reported (2026) Dyce | Retatrutide isn't just

The new triple agonists coming out in 2026 may even offer more benefits but we do need more long term research on this

December 17, 2024 Novo Nordisks Ozempic is under examination after two Danish studies found a potential connection between the drug and an increased risk of non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition that can lead to vision loss from reduced blood flow to the optic nerve

That long patent runway is why Lilly invests heavily in trial programs and pre-launch market positioning

For instance, Tesamorelin boosts fat breakdown, while Retatrutide improves glucose disposal

The FDA warns that, unlike FDA-approved drugs (Mounjaro and Zepbound), you cannot be sure of the purity, quality, efficacy, or safety of compounded tirzepatide

NAD determined that the evidence provided by Willow was insufficient to support its advertising claims